ENTO
Income statement / Annual
Last year (2024), Entero Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Entero Therapeutics, Inc.'s net income was -$18.06 M.
See Entero Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$29,274.00
|
$106,207.00
|
$537,400.00
|
$571,145.00
|
$976,982.00
|
$798,446.00
|
$753,998.00
|
$734,500.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$29,274.00
|
-$106,207.00
|
-$537,400.00
|
-$571,145.00
|
-$976,982.00
|
-$798,446.00
|
-$753,998.00
|
-$734,500.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$903.94
|
$5.03 M
|
$691,257.00
|
$38.32 M
|
$19.14 M
|
$8,680.67
|
$5,771.41
|
$2,395.48
|
$2,496.11
|
$1,398.06
|
| General & Administrative Expenses |
$14,561.00
|
$10.74 M
|
$11.99 M
|
$18.38 M
|
$7.29 M
|
$6,063.08
|
$7,450.37
|
$7,685.71
|
$4,129.05
|
$3,330.75
|
| Selling & Marketing Expenses |
$156,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$14,717.00
|
$10.74 M
|
$11.99 M
|
$18.38 M
|
$7.29 M
|
$6,063.08
|
$7,450.37
|
$7,685.71
|
$4,129.05
|
$3,330.75
|
| Other Expenses |
-$0.00
|
$0.00
|
-$232,741.00
|
$529,101.00
|
$211,430.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$15,621.00
|
$15.77 M
|
$12.68 M
|
$56.70 M
|
$26.43 M
|
$14,743.00
|
$13,431.00
|
$10,221.00
|
$8,654.18
|
$4,342.70
|
| Cost And Expenses |
$15,621.00
|
$15.77 M
|
$12.68 M
|
$56.70 M
|
$26.43 M
|
$14,743.00
|
$13,431.00
|
$10,221.00
|
$8,654.18
|
$4,342.70
|
| Interest Income |
$0.00
|
$2,531.00
|
$8,415.00
|
$1,173.00
|
$484.00
|
$0.00
|
$101.85
|
$875.20
|
$5,937.49
|
$1,587.53
|
| Interest Expense |
$0.00
|
$22,463.00
|
$15,879.00
|
$11,235.00
|
$5.84 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$48,946.00
|
$29,274.00
|
$29,271.00
|
$542,255.00
|
$565,345.00
|
$635.05
|
$798.45
|
$754.00
|
$734.50
|
$733.60
|
| EBITDA |
-$15,606.71 |
-$15.74 M |
-$14.51 M |
-$57.99 M |
-$26.26 M |
-$13.77 M |
-$12.63 M |
-$9.47 M |
-$7.92 M |
-$3.61 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$2.25
|
-$24,156.00
|
-$1.95 M
|
-$1.83 M
|
-$6.24 M
|
-$433,939.00
|
-$311,846.00
|
-$1.02 M
|
-$7.97 M
|
-$1.20 M
|
| Income Before Tax |
-$15,619.02
|
-$15.79 M
|
-$14.63 M
|
-$58.54 M
|
-$32.67 M
|
-$15,177.69
|
-$13,533.62
|
-$11,096.38
|
-$14,591.66
|
-$5,930.24
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$0.00
|
$0.00
|
$126,565.00
|
$26.52 M
|
$15.11 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$18.06 M
|
-$15.79 M
|
-$14.63 M
|
-$58.54 M
|
-$32.67 M
|
-$15.18 M
|
-$13.53 M
|
-$11.10 M
|
-$14.59 M
|
-$5.93 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.88 |
-46.96 |
-407.37 |
-27544.98 |
-48255.29 |
-28425.72 |
-36815.89 |
-43847.52 |
-94215.17 |
-25480.07 |
| EPS Diluted |
-5.26 |
-46.96 |
-407.37 |
-27544.98 |
-48255.29 |
-28425.72 |
-36815.89 |
-43847.52 |
-94215.17 |
-25480.07 |
| Weighted Average Shares Out |
$4.65 M
|
$336,342.00
|
$35,912.00
|
$2,125.17
|
$677.05
|
$533.94
|
$367.60
|
$253.07
|
$154.88
|
$232.74
|
| Weighted Average Shares Out Diluted |
$3.43 M
|
$336,342.00
|
$35,912.00
|
$2,125.17
|
$677.05
|
$533.94
|
$367.60
|
$253.07
|
$154.88
|
$232.74
|
| Link |
|
|
|
|
|
|
|
|
|
|
